Literature DB >> 9682272

Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas.

H J Lin1, N M Probst-Hensch, N C Hughes, G T Sakamoto, A D Louie, I H Kau, B K Lin, D B Lee, J Lin, H D Frankl, E R Lee, S Hardy, D M Grant, R W Haile.   

Abstract

N-acetyltransferase NAT1, together with enzymes CYP1A2 and NAT2, helps convert heterocyclic amines to mutagens. Epidemiologic studies of the association of variants of these enzymes with colorectal cancer may provide indirect support for a heterocyclic amine mechanism. We used single strand conformation polymorphism and heteroduplex analysis to screen fro mutations in the NAT1 coding region in a case-control study (n = 932) of colorectal adenomas, which are precursors to cancer. Thirteen different single-base mutations were found: C97T, C190T, T402C, G445A-G459A-T640G ( a combination of three mutations), C559T, G560A, A613G, A752T, T777C, G781A, and A787G. Function of novel mutations was tested by bacterial production of enzymes and measurements of Km, Vmax, and stability. However, on 24-control individuals and 18 cases carried an inactivating NAT1 mutation. When combined with our data on the NAT2 acetylation polymorphism, we saw no evidence for an association between N-acetyltransferases and prevalence of adenomas. Larger sample sizes are required for further evaluation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682272     DOI: 10.1097/00008571-199806000-00009

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  13 in total

Review 1.  A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review.

Authors:  Chunming Gong; Xueying Hu; Yong Gao; Yunfei Cao; Feng Gao; Zengnan Mo
Journal:  Med Oncol       Date:  2010-01-23       Impact factor: 3.064

Review 2.  Arylamine N-acetyltransferases: a structural perspective.

Authors:  Xiaotong Zhou; Zhiguo Ma; Dong Dong; Baojian Wu
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

3.  Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study.

Authors:  Tomoko Nakai; Daisuke Sakai; Yoshihiko Nakamura; Natsumi Horikita; Erika Matsushita; Mitsuru Naiki; Masahiko Watanabe
Journal:  BMC Med Genomics       Date:  2021-03-11       Impact factor: 3.063

Review 4.  Pharmacogenetics in inflammatory bowel disease.

Authors:  Marie Pierik; Paul Rutgeerts; Robert Vlietinck; Severine Vermeire
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

5.  Molecular epidemiology of colon cancer.

Authors:  Dong-Hyun Kim; Yoon-Ok Ahn
Journal:  Cancer Res Treat       Date:  2004-04-30       Impact factor: 4.679

6.  Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1.

Authors:  David F Barker; Anwar Husain; Jason R Neale; Benjamin D Martini; Xiaoyan Zhang; Mark A Doll; J Christopher States; David W Hein
Journal:  Pharmacogenet Genomics       Date:  2006-07       Impact factor: 2.089

7.  Identification of a minimal promoter sequence for the human N-acetyltransferase Type I gene that binds AP-1 (activator protein 1) and YY-1 (Yin and Yang 1).

Authors:  Neville J Butcher; Ajanthy Arulpragasam; Catherine Pope; Rodney F Minchin
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

8.  Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer.

Authors:  Jian-Min Yuan; Kenneth K Chan; Gerhard A Coetzee; J Esteban Castelao; Mary A Watson; Douglas A Bell; Renwei Wang; Mimi C Yu
Journal:  Carcinogenesis       Date:  2008-06-09       Impact factor: 4.944

9.  Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1.

Authors:  Y Zhu; D W Hein
Journal:  Pharmacogenomics J       Date:  2007-10-02       Impact factor: 3.550

Review 10.  Systematic meta-analyses and field synopsis of genetic association studies in colorectal adenomas.

Authors:  Zahra Montazeri; Evropi Theodoratou; Christine Nyiraneza; Maria Timofeeva; Wanjing Chen; Victoria Svinti; Shanya Sivakumaran; Gillian Gresham; Laura Cubitt; Luis Carvajal-Carmona; Monica M Bertagnolli; Ann G Zauber; Ian Tomlinson; Susan M Farrington; Malcolm G Dunlop; Harry Campbell; Julian Little
Journal:  Int J Epidemiol       Date:  2015-10-07       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.